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Purpose: To compare the therapeutic efficacy of pacli-
taxel plus cisplatin (arm A) versus gemcitabine plus cisplatin
(arm B) and arm A versus paclitaxel plus gemcitabine (arm
C) in chemotherapy-naive patients with advanced non–
small-cell lung cancer (NSCLC).
Materials and Methods: Patients were randomly as-
signed to receive either paclitaxel 175 mg/m2 (3-hour infu-
sion, day 1) or gemcitabine 1,250 mg/m2 (days 1 and 8)
both combined with cisplatin 80 mg/m2 (day 1) or pacli-
taxel 175 mg/m2 (3-hour infusion, day 1) combined with
gemcitabine 1,250 mg/m2 (days 1 and 8). Primary end
point was comparison of overall survival for B versus A and
C versus A. Secondary end points included response rate
and duration, progression-free survival, toxicities, quality
of life [QoL], and cost of treatment.
Results: Four hundred eighty patients (arm A, 159; arm
B, 160; arm C, 161 patients) were enrolled; all baseline
characteristics were balanced. Median survival times were
as follows: arm A, 8.1 months; arm B, 8.9 months; arm C,
6.7 months. Response rates were 31.8% for arm A, 36.6%
for arm B, and 27.7% for arm C. Other than myelosuppres-
sion (B v A, P < .005), no statistically or clinically significant
differences were observed for secondary end points. The
average treatment costs were 25% higher in arm C as
compared with arms A and B.
Conclusion: Gemcitabine plus cisplatin and paclitaxel
plus gemcitabine do not increase overall survival in patients
with advanced NSCLC as compared with paclitaxel plus
cisplatin. Treatment was well tolerated, and most QoL pa-
rameters were similar, but costs associated with the non-
platinum arm were highest.
J Clin Oncol 21:3909-3917. © 2003 by American
Society of Clinical Oncology.
IN EUROPE, lung cancer remains the first cause of cancer-related death in men and the fourth most common among
women.1 Approximately 85% of lung cancers are non–small-cell
lung cancers (NSCLCs).2 The distressingly low cure rate for
NSCLC (approximately 15% 5-year survival) can be attributed
to the high rate of unresectable disease at presentation and the
inability of systemic therapy to cure metastatic disease. For
patients with advanced NSCLC, treatment with chemotherapy
confers a modest survival benefit3-5 and short-lived improvement
of quality of life (QoL) when compared with radiotherapy alone
or best supportive care.5-7 In phase III trials, combinations of
cisplatin and one of the new active agents (ie, taxanes [paclitaxel
and docetaxel], gemcitabine, vinorelbine, and irinotecan) have
produced superior therapeutic results compared with cisplatin
alone8,9 and older cisplatin-based regimens.10-13 Moreover, some
of the new regimens are cost-effective.14-16 The combination of
cisplatin and gemcitabine is one of the most active newer
regimens.17 Despite modern antiemetic and hydration regimens,
cisplatin has substantial side effects that limit its use.18,19 There are
several ways to circumvent cisplatin-induced toxicities, including
omitting cisplatin and replacing it with a cytotoxic drug with similar
activity. One such regimen, paclitaxel plus gemcitabine, has been
shown in a phase II study to produce a major response rate of 24%
with acceptable toxicity.20 On the basis of these considerations, the
European Organization for Research and Treatment of Cancer
(EORTC) Lung Cancer Group conducted a randomized, phase III
study to compare the best arm of our previous phase III study in
patients with advanced NSCLC, ie, cisplatin plus paclitaxel,11 with
cisplatin-gemcitabine and paclitaxel-gemcitabine combinations in
chemotherapy-naive patients with advanced NSCLC.
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MATERIALS AND METHODS
Patients
Patients with histologically or cytologically confirmed NSCLC stage IIIB
(caused by malignant pleural effusion or supraclavicular lymph nodes only)
and stage IV disease according to the revised staging system of the American
Joint Committee on Cancer21 were entered onto the study. Additional
eligibility criteria included age between 18 and 76 years, WHO performance
status (PS)  2, measurable disease, no previous chemotherapy with the
exception of prior neoadjuvant or adjuvant chemotherapy that ended more
than 1 year before entry, and adequate hematologic, renal, and hepatic
function. Previous radiotherapy was allowed provided that an interval of at
least 4 weeks had elapsed and the radiotherapy field did not include all
measurable lesions used as target lesion. Patients with preexisting brain
metastases or leptomeningeal disease who were treated with radiotherapy,
stable without medications (eg, corticosteroids), and asymptomatic were
eligible The study was approved by the EORTC Protocol Review Committee
and all ethics committees of the participating institutions. Written informed
consent had to be obtained from all patients and documented according to
national regulatory requirements and to the local institution rules. In the
course of the trial, we discovered that the written informed consent could not
be documented for 33 patients (6.9%) included in the trial. Although we
could not retrieve the documentation of the informed consent, all these
patients were checked on availability of the other source data. For all these
patients, the responsible investigator has stated that he/she fully informed the
patient orally on all aspects of the trial and certifies that each patient agreed
to participate in the trial.
At study entry, the following investigations were performed: full history
and physical examination, complete blood cell count and differential,
chemistries, creatinine clearance, ECG, and chest x-ray. All investigations
were repeated before every cycle. Computed tomography scans and ultra-
sound were performed to document disease extent optimally and to evaluate
response to treatment according to WHO guidelines.22 Toxicity was scored
according to the National Cancer Institute common toxicity criteria scale.23
Therapy
Patients were randomly assigned to receive paclitaxel 175 mg/m2 on day
1 followed by cisplatin 80 mg/m2 on day 1 (regimen A), gemcitabine 1,250
mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1 after gemcitabine
(regimen B), or paclitaxel 175 mg/m2 on day 1 followed by gemcitabine
1,250 mg/m2 on days 1 and 8 (regimen C). All treatment cycles were
repeated every 3 weeks. Cisplatin was dissolved in 500 mL of normal saline
or 5% dextrose and infused along a program of forced diuresis that included
at least 2 L of fluids. Paclitaxel was dissolved in 500 mL of normal saline or
5% glucose and administered as a 3-hour intravenous infusion with prophy-
lactic medication to prevent hypersensitivity reactions. Gemcitabine was
dissolved in 500 mL of normal saline and administered as a 30-minute
intravenous infusion. Prophylactic antiemetics during and after cisplatin
administration typically consisted of ondansetron and dexamethasone. Treat-
ment was continued for at least two cycles unless this was clearly not in the
patient’s best interest. Treatment was always interrupted in case of intoler-
able toxicity, patient refusal, or disease progression. Responding patients
received a maximum of six cycles. Dose adjustments and delays for toxicity
were defined as per protocol.
QoL Assessment
QoL was evaluated in a longitudinal design in all randomly assigned
patients. QoL assessments were performed at baseline, at the end of each
cycle of treatment, every 6 weeks after the end of treatment until progression
of the disease (PD), at PD, and thereafter every 3 months until death using
the EORTC QoL core questionnaire (QLQ-C30, version 3.0) in conjunction
with the EORTC lung module (LC-13).
Health Economics
The medical resource data collected comprised primary chemotherapy,
hospital admissions (overnight stays or days spent in day clinics), consulta-
tions with cancer specialists and family doctors, premedication before
administration of paclitaxel, antiemetics, cytotoxic agents, use of blood
transfusions, and second-line therapy. Because the large majority of the
patients in the trial (77%) were recruited by hospitals in the Netherlands,
2002 national tariffs for the Dutch health insurance system were used as unit
prices for the determination of costs.
Statistics
Randomization was performed centrally by the EORTC Data Center after
stratification for PS (0 to 1 v 2), stage of disease (IIIB v IV), and institute,
using the minimization technique.24 The primary end point was the pairwise
comparison of overall survival between each of the two experimental arms
and the control arm (regimen B v A and C v A); secondary end points
included response rate, duration of response, progression-free survival,
toxicities, QoL, and cost of treatment. Duration of survival and progression-
free survival were calculated from the date of randomization. For the
responders, duration of response was measured from the date of start of
treatment to the date of objective PD; patients were censored if new
treatment was started before PD. Assuming a median survival in the control
arm of approximately 8 months,13 a total of 369 deaths were necessary to
detect an absolute increase in median survival of 4 months with a two-sided
type I error of 0.02 (to keep the overall type I error of 0.05) and a power of
80%.25 Assuming a 36-month duration of recruitment and another 12 months
of follow-up, 450 patients (150 to each treatment arm) needed to be
randomly assigned to achieve these statistical requirements. An interim
analysis was scheduled after 60 deaths and was submitted to an independent
data monitoring committee. The predefined criteria for considering trial
closure were a response rate of less than 25% in one of the treatment arms
or association of a treatment arm with excessive toxicity. For the time-to-
event end points, the decision rule was based on alpha-spending function26
using an O’Brian-Fleming boundary.27
All analyses, except for response rate, were performed on all randomly
assigned patients according to the intent-to-treat principle. Response rate
analysis was based on eligible patients only. Overall survival curves and
progression-free survival curves were estimated by the Kaplan-Meier tech-
nique,28 and pairwise differences for time-to-event end points were assessed
using the log-rank test29 at 0.02 two-sided  level. To adjust for confounding
variables, the Cox proportional hazards model with backward variable
selection procedure was used.30 The multivariate model was based on the
following factors of possible prognostic value: stage (IIIB v IV), PS (0 to 1
v 2), histologic subtype (squamous v nonsquamous), sex, and treatment arm.
Pairwise comparisons of response rates were performed using a Cochran
Mantel-Haenszel test at .02 two-sided  level. Pairwise comparisons of the
rates of grade 3/4 toxicity between the standard arm and each of the
experimental arms were performed using a Fisher’s exact test at .02
two-sided  level. Reported P values concerning differences in toxicity
should be interpreted with caution.
Data on QoL were scored according to the algorithm described in the
EORTC QLQ-C30 scoring manual.31 Nonoverlapping windows were
constructed to assign the QoL forms received to one of the assessment
points. Data were analyzed using descriptive statistics for the subscales
for each study arm at each of the assessment points. A mixed model was
applied using a one-step autoregressive covariance structure to investi-
gate pairwise comparisons of changes in QoL score over time. All tests
were performed two-sided at a significance level fixed at  5%.
Statistically significant changes of  10 effect points were defined as
clinically significant.32
RESULTS
Between August 1998 and July 2000, 480 patients were
randomly assigned from 29 institutions. The outline of the trial
is provided in Figure 1. Patient characteristics (Table 1) were
well balanced among the three treatment arms; the majority of
patients had a good PS, adenocarcinoma, and metastatic disease.
The number of cycles and relative dose-intensity administered in
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the three treatment arms are provided in Table 2. The median
number of cycles was lower in arm C (four cycles) as
compared with arms A and B (five cycles). Drug exposure,
expressed as relative dose-intensity, was not different be-
tween the treatment arms.
Survival and Progression-Free Survival
After a median follow-up of 28 months, 439 patients (91.5%)
had died: 145 in arm A, 143 in arm B, and 151 in arm C. In 391
(89.1%) of these patients, the cause of death was tumor progres-
Fig 1. Outline of the study. Pacli, pacli-
taxel; cDDP, cisplatin; gemc, gemcitabine;
PD, progression of disease; PFS, progres-
sion-free survival.
Table 1. Patient Characteristics
Characteristic
Arm A (n  159) Arm B (n  160) Arm C (n  161)
No. % No. % No. %
Ineligible 8 5.0 8 5.0 6 3.7
Age, years
Median 57 57 56
Range 27-75 28-75 31-75
Sex
Male 95 59.7 113 70.6 110 68.3
Female 64 40.3 47 29.4 51 31.7
WHO PS
0 35 22.0 40 25.0 38 23.6
1 105 66.0 102 63.8 104 64.6
2 19 11.9 18 11.3 19 11.8
Histology
Squamous 30 18.9 41 25.6 35 21.7
Adenocarcinoma 64 40.3 73 45.6 64 39.8
Large cell 63 39.6 40 25.0 54 33.5
Other 2 1.2 5 3.1 7 4.3
Unknown 0 0 1 0.6 1 0.6
Stage
IIIB 29 18.2 33 20.6 29 18.0
IV 130 81.8 126 78.8 132 82.0
Other 1 0.6
Prior surgery
No 130 81.8 140 87.5 128 79.5
Yes 23 14.5 17 10.6 24 14.9
Explorative thoracotomy 5 3.1 1 0.6 7 4.3
Other 1 0.6 2 1.3 2 1.2
Prior radiotherapy
No 129 81.1 137 85.6 132 82.0
Yes 30 18.9 23 14.4 29 18.0
Prior chemotherapy
No 157 98.7 159 99.4 154 95.7
Yes* 2 1.3 1 0.6 7 4.3
Abbreviation: PS, performance status.
*(Neo)adjuvant chemotherapy ( 1 year before entry).
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sion. Tables 3 and 4 summarize treatment outcome. There were
no statistically significant differences in survival times between
the reference arm and the two experimental arms. Progression-
free survival was not different between treatment arms, but there
was a strong trend for shorter progression-free survival in arm C.
Figures 2 and 3 depict the overall survival and progression-free
survival by treatment arm.
Multivariate analysis for survival retained only PS 2 as a
significant negative prognostic factor for survival; patients
with WHO PS 0 to 1 had a median survival of 8.5 months,
whereas those with WHO PS 2 had a median survival of 3.3
months (P  .0001).
Tumor Response
Only one complete response (arm B) was observed (Table 4).
The partial response rate was 32% in arm A, 37% in arm B, and
28% in arm C (P was not significant for both comparisons).
Duration of response was similar between arms A and B and
showed a strong trend for shorter duration for arm C as
compared with the reference arm.
Toxicity
There were twelve toxic deaths: four in arm A (2.5%), two in
arm B (1.2%), and six in arm C (3.7%). Of these patients, nine
had PS 1 at randomization and three had PS 0.
Grade 3 and 4 toxicities that occurred in at least 5% of patients
are listed in Table 5. Hematologic toxicity was the most frequent
side effect in all three arms. Nine patients (two in arm A, four in
arm B, and three in arm C) developed grade 3 febrile neutrope-
nia, whereas neutropenia grade 3 or 4 occurred in 34.0% of
patients in arm A, 43.1% in arm B, and 30.4% in arm C (P not
significant). Grade 3 and 4 thrombocytopenia occurred more
frequently in arm B (36.3%) as compared with arm A (1.3%; A
v B, P .0001). Anemia grade 3 and 4 was also more frequently
observed in arm B (11.9%) as compared with arm A (3.1%; A v
B, P .0048). This is reflected in the proportion of patients with
hemorrhagic episodes (6.4% in arm A and 15.8% in arm B; A v
B, P  .0208) and transfusions (23.9% in arm A and 43.7% in
arm B; A v B, P .0002), 95% of which were RBC transfusions.
No statistically significant differences for the comparison be-
Table 2. Chemotherapy Administered
Arm A (n  159) Arm B (n  160) Arm C (n  161)
No. % No. % No. %
No. of cycles
0 5 3.1 2 1.3 3 1.9
1 15 9.4 10 6.3 19 11.8
2 30 18.9 27 16.9 34 21.1
3 10 6.3 11 6.9 9 5.6
4 18 11.3 20 12.5 24 14.9
5 9 5.7 10 6.3 8 5.0
6 72 45.3 80 50.0 64 39.8
Median No. of cycles 5 5 4
RDI paclitaxel, %
Median 100 100.5
Range 43-109.5 6.8-109.5
RDI gemcitabine, %
Median 94.7 98.6
Range 35-105 14.6-107.4
RDI cisplatin, %
Median 99.9 96.4
Range 16.9-107.6 15.9-106.4
NOTE. Relative dose-intensity (RDI) is calculated as the ratio of the observed dose-intensity (milligrams per square meter received
by the patient divided by the actual total treatment duration in weeks) to the dose-intensity planned by the protocol. RDI is presented
for all patients who started the protocol treatment.
Table 3. Survival and Progression-Free Survival
Arm A (n  151) Arm B (n  152) Arm C (n  155) P
Survival, months
Median 8.1 8.9 6.7 A v B, .668
95% CI 6.2 to 9.9 7.8 to 10.5 5.9 to 7.6 A v C, .108
1-Year survival, %
Median 35.9 33.1 26.7
95% CI 28.4 to 43.3 25.8 to 40.4 19.9 to 33.6
PFS, months
Median 4.2 5.1 3.5 A v B, .339
95% CI 3.2 to 4.5 4.5 to 5.7 2.9 to 4.3 A v C, .044
Abbreviation: PFS, progression-free survival.
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tween arm A and C with regard to these toxicities were found.
No significant differences were observed between the treatment
arms for any of the other grade 3 and 4 toxicities, including
anorexia, nausea, and vomiting.
Second-Line Therapies
Of all patients entered onto the trial, 278 (57.9%) received at
least one form of further antitumoral treatment after PD and were
distributed similarly across the treatment arms (57.7% in arm A,
59.4% in arm B, and 59.6% in arm C). The study protocol did
not give any recommendations on second-line therapy. More
than 60% of these patients received radiotherapy, and a third
received chemotherapy first as second-line therapy. Again, type
of first treatment at PD was similarly distributed among the
treatment arms. Of note, of the 28 patients randomly assigned to
arm C who received second-line chemotherapy, 24 patients were
treated with a platinum combination.
QoL Analysis
Compliance at baseline and throughout the active treatment
period was greater than 60% but decreased dramatically at cycle
6 (47 forms received of the 183 forms expected; 25.7%) and for
assessments during follow-up. This analysis is therefore re-
stricted to the treatment period. There was no significant differ-
ence in compliance at the different assessment points between
the two experimental arms and the standard arm. When compar-
ing arm B with arm A, no significant difference in global QoL
(P  .816) was observed (Fig 4). A statistically (P  .0001) and
clinically significant overall improvement was observed for
peripheral neuropathy and alopecia in arm B compared with arm
A. Nausea and vomiting increased significantly with time but at
a similar rate in both arms. Clinically relevant improvement was
observed for coughing and insomnia in both arms.
No significant overall treatment effect was found for global
QoL (P  .232) comparing arm C with arm A (Fig 4). There
was a difference between the two arms in the way global QoL
evolved with time. In arm A, global QoL score increased 10
points between baseline and the end of cycle 2 and thereafter
gradually decreased to baseline values at the end of cycle 6.
In arm C, the global QoL score slightly increased between
baseline and the end of cycle 1 and then stabilized around
baseline value. Nausea and vomiting increased with time in
Fig 2. Survival by treatment arm. O, observed; N, number; Pacli, paclitaxel;
CDDP, cisplatin; Gemc, gemcitabine.
Fig 3. Progression-free survival by treatment arm. O, observed; N, number;
Pacli, paclitaxel; CDDP, cisplatin; Gemc, gemcitabine.
Table 4. Response and Response Duration (eligible patients)
Variable
Arm A (n  151) Arm B (n  152) Arm C (n  155)
PNo. % No. % No. %
Complete response 0 1 0.7 0
Partial response 48 31.8 55 36.2 43 27.7
No change 52 34.4 56 36.8 55 35.5
Progressive disease 36 23.8 25 16.4 35 22.6
Early deaths 8 5.3 7 4.6 11 7.1
Not assessable 7 4.6 8 5.3 11 7.1
Response rate, %
Median 31.8 36.8 27.7 A v B, .355
95% CI 24.4 to 39.2 29.2 to 44.5 20.7 to 34.8 A v C, .440
Response duration,* months
Median 8.0 7.4 6.9 A v B, .363
95% CI 6.4 to 11.0 6.4 to 9.5 5.7 to 7.5 A v C, .040
*Responding patients only.
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both arms, but less so in arm C. The difference was statisti-
cally significant (P  .0047) but became clinically relevant
only at the end of cycle 5.
Resource Use
A detailed analysis of resource use data is the subject of a
separate manuscript. Here, we report the base case point esti-
mates of the average total cost (ATC) per patient without the
correction for censoring, averaged over all randomly assigned
patients and broken down into the principal cost categories
(Table 6). ATCs are highest in arm C and statistically signifi-
cantly lower in arm B than in arm A. Costs of hospital
admissions for treatment of adverse events and disease symp-
toms and for second-line therapy were quite similar in the three
arms, so the differences in ATC are mainly due to differences in
the costs of administration of chemotherapy and of the cytotoxic
agents themselves. Treatment C was the least costly to admin-
ister, but the cytotoxic agents cost more than the double of those
used for treatment B. The costs of the cytotoxic agents for
treatment A were more than 50% higher than those for treatment
B, but this is partially balanced by lower costs of administration
of treatment A.
DISCUSSION
The results of the randomized phase III study presented here
show that neither cisplatin-gemcitabine nor paclitaxel-gemcitab-
ine chemotherapy is superior to the cisplatin-paclitaxel combi-
nation for patients with advanced NSCLC in regard to overall
survival, progression-free survival, and response rate. The me-
dian survival obtained in the reference arm, paclitaxel plus
Table 5. Grade 3 and 4 Toxicities (NCI-CTC grading system)
Arm A (n  159) Arm B (n  160) Arm C (n  161)
PNo. % No. % No. %
Leucocytopenia 19 11.9 43 26.9 34 21.1 A v B, .001
A v C, .035
Neutropenia 54 34.0 69 43.1 49 30.4 A v B, .108
A v C, .550
Platelets 2 1.3 58 36.3 10 6.2 A v B,  .001
A v C, .035
Anemia 5 3.1 19 11.9 6 3.7 A v B, .005
A v C, .999
Febrile neutropenia 2 1.3 4 2.5 3 1.9 A v B, .685
A v C, .999
Nausea 13 8.2 20 12.5 10 6.2 A v B, .270
A v C, .524
Vomiting 14 8.8 20 12.5 9 5.6 A v B, .365
A v C, .287
Lethargy 15 9.4 19 11.9 18 11.2 A v B, .587
A v C, .714
Dyspnea 13 8.2 17 10.6 20 12.4 A v B, .566
A v C, .427
Other skin toxicity* 17 10.7 10 6.3 19 11.8 A v B, .165
A v C, .860
Cancer pain 21 13.2 20 12.5 22 13.7 A v B, .869
A v C, .999
Abbreviation: NCI-CTC, National Cancer Institute common toxicity criteria.
*Including alopecia.
Fig 4. Global quality of life. Arm A versus arm B (A) and arm A versus arm C (B). Pacl, paclitaxel; CDDP, cisplatin; Gemc, gemcitabine.
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cisplatin, was shorter than that reported in our previous random-
ized phase III trial, ie, 8.1 months (95% CI, 6.2 to 9.9 months)
versus 9.7 months (95% CI, 8.2 to 11.9 months)11 but compa-
rable to that observed in the reference arm (cisplatin plus
paclitaxel) in the recently reported four-arm randomized study of
the Eastern Cooperative Oncology Group.17 This can be ex-
plained by the fact that in the present study, approximately 80%
of the patients entered had stage IV disease, versus 61% in our
previous study. A strong (but according to the predefined
statistical criteria, non significant) trend in the nonplatinum arm
toward lower overall and progression-free survival was observed
as compared with the reference arm. One may question whether
the design of the study, which sought to show an improvement
in median survival of 50%, was too optimistic. Indeed, the phase
I/II study of the paclitaxel-gemcitabine combination that formed
the basis of arm C found a median survival of only 5.4 months
(95% CI, 4.4 to 8.2 months).20 On the other hand, to power a
three-arm study for a more realistic 30% increase in median
survival would require approximately 1,000 patients to be
assigned. Three phase III studies33-35 also failed to demonstrate
a significant difference in survival between advanced NSCLC
patients treated with platinum-based versus nonplatinum-based
chemotherapy. In the Italian study,35 as in our study, a strong
trend for inferior progression-free survival was observed in
the nonplatinum arm. However, all these studies, as the study
under discussion, were designed to show superiority of the
nonplatinum regimens either in regard to survival or response.
Equivalence testing of platinum and nonplatinum combina-
tions with the newer agents await adequately powered stud-
ies,36 ie, studies including much larger numbers of patients.
Multivariate analysis identified PS 2 as the sole factor nega-
tively affecting survival. Retrospective reviews of randomized
phase III studies of cisplatin-based chemotherapy have consis-
tently shown that PS 2 patients have a poor survival.8,37-39 From
a reanalysis of E1594,40 it was concluded that the disease
process rather than treatment was the cause of the poor overall
survival and the observed toxicity in PS 2 patients. Although we
did not analyze whether the incidence of grade 3 and 4 toxicities
was more prevalent in PS 2 patients, none of the 12 toxic deaths
occurred in this patient group.
Because the role of chemotherapy in the treatment of ad-
vanced NSCLC is palliative at best, side effects of treatment
become a major issue. The side effects of cisplatin limit its use,
especially in older patients with concomitant cardiorespiratory
disease, and are probably also responsible for the poor accep-
tance of cisplatin-based chemotherapy in the routine treatment of
advanced NSCLC by the medical community. In this study, the
only toxicity that differed significantly among the three treat-
ment arms was myelosuppression, being more common in arm B
versus arm A, but this did not lead to clinically relevant sequelae.
The proportion of patients experiencing grade 3 and 4 toxicities
typically associated with the use of cisplatin (eg, nausea and
vomiting, renal toxicity, and neurotoxicity) was similar in all
arms. This result is at variance with previous studies comparing
platinum-based chemotherapy with nonplatinum-based chemo-
therapy for advanced NSCLC patients.8,33,35,41 However, two
recent studies also found no difference in toxicity when com-
paring platinum-treated with nonplatinum-treated patients.34,42
QoL analysis during treatment complements the toxicity find-
ings. Global QoL score improved temporarily in all three arms
and then returned to baseline values. Negative effects on QoL
typically associated with the use of cisplatin, such as nausea and
vomiting, were different at a clinically relevant level in the
noncisplatin arm only at cycles 5 and 6 and is particularly
sensitive to selection bias because of the high number of
drop-outs. This is the first study to demonstrate that global QoL
in patients with advanced NSCLC is similar for patients treated
with platinum-based chemotherapy versus those treated with
nonplatinum-based chemotherapy. Several authors advocate
short duration of initial chemotherapy (three to four courses) for
patients with advanced NSCLC, mainly on the basis of findings
of two randomized trials.43,44 The median number of courses
administered in the two platinum doublets was five. In these
arms, survival (8.1 months and 8.9 months) was numerically
superior to median survivals as reported by Smith et al (6
months)43 and Socinski et al (6.6 months).44 Whether the
maximum number of courses in the next phase III study should
be limited to four or even fewer is still a matter of debate within
the EORTC Lung Study Group.
There is increasing pressure to demonstrate the value of new
treatments within the health care budget. From the results of the
economic evaluation reported here, it may be concluded that the
paclitaxel-gemcitabine arm is an inferior option compared with
the two cisplatin-containing regimens because the clinical out-
comes are no better, both in regard to survival and QoL, whereas
the average medical costs are higher. Despite its higher incidence
of severe hematologic toxicities and the consequent greater need
for blood transfusions, the medical costs of the gemcitabine-
cisplatin regimen are significantly smaller than those of the
paclitaxel-cisplatin regimen. Any medical economic evaluation
must by necessity rely on resource unit prices from a particular
health care setting and point in time for the determination of
direct medical costs engendered by treatment. Because absolute
Table 6. Summary of Mean Cost Estimates, in Euros, 2002 Values
Cost Component Arm A Arm B Arm C
Hospital costs, total 5,214 6,471 4,459
Overnight stays 5,058 5,475 3,187
Day clinic stays 156 996 1,262
Administration of chemotherapy 2,909 4,059 2,201
Other reasons 2,305 2.412 2,258
Specialist and GP consultations* 97 97 97
Cytotoxics† 8,654 5,234 11,108
Blood transfusions 209 367 140
Second-line therapy 1,893 1,840 1,643
ATC per patient 16,067 14,009 17,447
Abbreviations: GP, general practitioner; ATC, average total cost; CTG, Dutch
National Health Insurance Committee.
*Costs calculated assuming a single-visit co-pay (CTG code 010122) because the
mean number of specialist consultations is between five and seven in the three
groups.
†Chemotherapy includes supportive care (ie, premedication before paclitaxel and
antiemetics).
3915NOVEL CHEMOTHERAPIES FOR ADVANCED NSCLC
and relative unit prices diverge between health care settings in
different countries, the generalizability of economical evaluation
is a difficult and controversial issue. One would first have to
compare unit prices and resource use pattern reported in this
evaluation with those prevailing in the health care setting of
interest. If both are considered sufficiently similar, the results
reported here could reasonably be assumed applicable in a
qualitative sense. However, if precise quantitative estimates are
needed, an independent economic evaluation should be per-
formed, but available modeling techniques would ease the
burden of doing so.
In conclusion, this study demonstrates that the two drug
combinations of gemcitabine plus cisplatin and paclitaxel plus
gemcitabine do not increase overall survival for the palliative
treatment of advanced NSCLC as compared with paclitaxel plus
cisplatin. There was a trend toward lower progression-free
survival and shorter duration of response for the nonplatinum
arm. Treatment was well tolerated and most QoL parameters
were equal in all three arms, but the costs associated with the
nonplatinum arm were highest. The EORTC Lung Cancer Group
will continue to use a platinum-containing regimen as the
reference arm in the next randomized study that will be con-
ducted in patients with advanced NSCLC.
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